Gangliosides offer partial protection in experimental allergic neuritis.
The effect of gangliosides on the clinical course of experimental allergic neuritis was tested in Lewis rats sensitized with bovine intradural root myelin in complete Freund's adjuvant. A mixture of bovine brain gangliosides (GM1, GD1a, GD1b, GT1b) was injected intramuscularly at a daily dose of 20 mg per kilogram of body weight, beginning 6 days after inoculation. The results from seven different experiments show that in most cases, the administered gangliosides were partially protective. Particularly striking was the reduction in mortality rate to half or less of saline-injected controls. Cumulative clinical index scores were also significantly lower with ganglioside treatment in five of the seven experiments. The cause of the wide variability is not known, but it was noted that better results were obtained when the animals were sensitized with freshly isolated myelin.
Ledeen
R W
RW
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461.
Oderfeld-Nowak
B
B
Brosnan
C F
CF
Cervone
A
A
D000818:Animals; D005732:Gangliosides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009444:Neuritis, Autoimmune, Experimental / Q000188:drug therapy* / Q000401:mortality; D051381:Rats; D011917:Rats, Inbred Lew
D005732:Gangliosides